410 results about "Colon cancer cell" patented technology

A DNA vaccine effective for eliciting an immune response against cells that present a carcinoembryonic antigen (CEA) comprises a DNA operably encoding a CEA and a DNA operably encoding a CD40 ligand, SEQ ID NO:1 and SEQ ID NO: 2, respectively, or its homotrimer, CD40LT. The DNA vaccine can be incorporated in a delivery vector such as an attenuated live bacterium or virus, or a liposome carrier. In a method embodiment, the DNA vaccine is administered orally to a mammal, such as a human, to elicit an immune response against CEA presenting cells such as colon cancer cells. A preferred method embodiment includes the additional step of treating the mammal with recombinant antibody fusion protein huKS1/4-IL2 to enhance the immune response effectiveness of the vaccine.

The invention discloses bifidobacterium bifidum capable of remarkably relieving constipation and application thereof and belongs to the technical field of microorganisms. The bifidobacterium bifidum CGMCC NO.13632 can well tolerate simulative gastrointestinal fluid, can be well attached to colon cancer cells HT-29, and can remarkably increase the water content of excrement of constipation mice and shorten the first tarry stool time. On the aspect of increasing the small intestine driving rate, the bifidobacterium bifidum CGMCC NO.13632 is superior to cathartic phenolphthalein, a best effect is shown, secretion of gastrointestinal regulatory peptide relevant to constipation in serum is also adjusted while constipation pathological factors are remarkably improved, and the bifidobacterium bifidum does not have toxic and side effects of medicine for treating constipation, and is a first choice for preventing and treating constipation. The bifidobacterium bifidum CGMCC NO.13632 is used for preparing pharmaceutical compositions and fermented food for relieving constipation, and has very wide application prospects.

The present invention features methods and formulations or compositions for the treatment of colon cancer, and particularly for the inhibition, prevention and/or reduction of cancerous cell growth, as well as the destruction of early stage cancerous cells within the colon region of a mammal, wherein the formulations and compositions comprise an identified amount or concentration of a processed Morinda citrifolia product or an active ingredient there from, as obtained from the Indian Mulberry plant.

An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitising a cancer cell to a cytotoxic compound. In addition, a cancer Vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate.

The invention provides a targeted adriamycin-loaded magnetic nanoparticles and a preparation method and application, and belongs to the magnetic nanoparticles and preparation thereof. The targeted adriamycin-loaded magnetic nanoparticles are formed by taking the magnetic Fe3O4 nanoparticles formed by using dopamine to wrap as a core, and an EGFR antibody covalently coupled on the surface of the magnetic Fe3O4 nanoparticles through 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride or N-hydroxysuccinimide, and adriamycin non-covalently coupled to the surface of the nanoparticles. The nanoparticles provided by the invention have good target recognition capacity to the colon cancer cell DLD-1, can effectively enter the internal of the DLD-1 cell, has excellent photo-thermal killing ability on the DLD-1 cell, can be used for the photo-thermal treatment and medicine chemotherapy of the colon cancer cell, and has a good magnetic resonance imaging function.

The invention discloses a Ziyang selenium-rich green tea selenium-containing polysaccharide, which comprises the following components in percentage by mass: 1.5-8.5 ppm selenium and the balance of heterosaccharide. The heterosaccharide comprises the following components in percentage by mol: 3.3-5.3% of mannitose, 1-2% of ribose, 3.5-5% of rhamnose, 2-3.5% of glucuronic acid, 2.6-3.8% of galacturonic acid, 30-34.2% of glucose, 3.6-5.6% of xylose, 19.8-23.2% of galactose and 21.5-25.6% of arabinose. The invention also provides a preparation method and application of the Ziyang selenium-rich green tea selenium-containing polysaccharide. The preparation method is simple and convenient, has the advantage of low cost, and is suitable for popularization; and the selenium-containing polysaccharide has the action of enhancing immunity, has obvious inhibiting actions on growth of colon cancer cells, and has obvious protective actions on hepatic injury.

The invention discloses a compound with an MEK (Mitogen-activated and Extracellular signal-regulated Kinase) inhibiting function as well as a preparation method and application of the compound. The structure of the compound disclosed by the invention is as shown in a formula (I). The preparation method of the compound disclosed by the invention comprises the steps of forming a coumarin ring by adopting a Pechmann reaction mainly and carrying out structural modification of different sites. In the binding experiment of the compound disclosed by the invention and MEK, the binding activity is up to 54.57nM; the anti-proliferation effect IC50 (half maximal inhibitory concentration) value on the melanoma cell A375 is up to 1.23 micrometers; the anti-proliferation effect IC50 value on the colon cancer cell HT-29 is up to 2.13 micrometers; and the activity is higher than that of a positive control U0126. The novel structure type coumarins compound with the MEK inhibiting function shows good MEK binding activity, MEK inhibiting activity, ERK (Extracellular signal Regulated Kinase) pathway inhibiting activity, anti-tumor effect and antiviral effect and has broad application value. The formula (I) is as shown in the specification.

Colon cancer cells in a sample are screened by analyzing the amount of expression of at least 2 or more genes or products thereof selected from the group of genes listed in Tables 1 and 30. As compared to conventional method, patients having colon cancer can be detected with higher accuracy. Colon cancer cells in stool are also screened by analyzing expression of genes selected from the group of genes listed in Table 37.

The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and beta-HCG.

Disclosed is an anti-tumor drug with nor-icariin as the effective ingredient. Pharmacological test effect proves that the nor-icariin has the activity to inhibit the production of cellular lipid, can reduce the production of cellular fatty acid by inhibiting the activity of FAS, has a function of inhibiting the production and causing withering of microvascular endothelial cells, shows a broad-spectrum anti-tumor function in a cytotoxicity test of thirty-three tumor cell strains of a human body, and shows a function in strongly inhibiting the production of tumor, such as prostate cancer cells LnCAP, lung cancer cells NCI-H23 and colon cancer cells HCT-116 of a human body in a tumor transplantation nude mice model test. A pharmacokinetics test of the nor-icariin in the body of a little mouse proves that the nor-icariin can be kept with a certain concentration, good for better anti-humor effect. The acute toxicity test of the nor-icariin in the body of the mouse shows nontoxicity; therefore the nor-icariin is proved to be a newly-developed broad spectrum anti-humor drug with broad development prospect.

The present invention discloses a cyclic pentapeptide with anti-tumour activity, which is cyclic (leucyl-N-methylleucyl-leucyl-leucyl-N-methylleucyl) and the constitutional formula of which is shown in the formula (I). The cyclic pentapeptide of the present invention is separated from galaxaura filamentosa in the South China Sea, and in vitro experiments show that the cyclic pentapeptide has strong inhibiting effect on human hepatoma cell lines (HepG2), human hepatoma cell lines (BEL-7402), human mammary cancer cell lines (MCF-7), human colon cancer cell lines (LOVO), human lung cancer cell lines (PC84045) and human nasopharyngeal cancer (CNE) and can keep the mitotic cycle of BEL-7402 hepatoma cells in G2/M phase. The present invention provides a pilot compound for the research and the development of new anti-tumour drugs and is valuable for the exploitation of the marine pharmaceutical resources of China.

The invention discloses a nucleic acid adapter used for detecting a human high-metastasis colon cancer cell strain LoVo and a detection kit. The nucleic acid adapter is one of a nucleic acid adapter J1, a nucleic acid adapter J3, a nucleic acid adapter J4 and a nucleic acid adapter J7; the nucleotide sequence of the nucleic acid adapter J1 is a DNA fragment shown as SEQ ID NO.1; the nucleotide sequence of the nucleic acid adapter J3 is a DNA fragment shown as SEQ ID NO.2; the nucleotide sequence of the nucleic acid adapter J4 is a DNA fragment shown as SEQ ID NO.3; the nucleotide sequence of the nucleic acid adapter J7 is a DNA fragment shown as SEQ ID NO.4. The nucleic acid adapter is low in immunogenicity, small in molecular weight, easy to store and label and capable of serving as the detection kit to detect the human high-metastasis colon cancer cell strain LoVo.

The invention relates to novel beta-chloroethylnitrosourea compounds, and a synthesis method and application thereof. The structure of the beta-chloroethylnitrosourea compounds is disclosed as general formula (II). The in-vitro antitumor screening test on the compounds disclosed as general formula II proves that the compounds disclosed as general formula I have obvious inhibiting action on human cerebral nerve glioma cells SF763, SF767, SF126 and SF188, human colon cancer cell HT29, mouse leukaemia cell L1210 and many other tumor cell lines and have higher tumor inhibiting activity than the existing CENU and CENU/O6-benzylguanine combined medicine.

2-indolyl imidazo[4,5-d]phenanthroline compounds of Formula I that are capable of intracellular chelation of transition metals and of exerting antiproliferative effects in cancer cells, that are cytostatic and/or cytotoxic, are provided. Compounds of Formula I can also induce apoptosis in cancer cells and are thus capable of exerting a cytotoxic effect on cancer cells. The compounds of Formula I are also capable of selectively inhibiting the proliferation of one or more of prostate cancer cells, colon cancer cells, non-small lung cancer cells and leukemia cells. The compounds of Formula I are also capable of increasing the expression of the zinc-regulated tumour suppressor, KLF4 and thus are useful in inhibiting the proliferation of cancer cells in which KLF4 functions as a tumour-suppressor, including, but not limited to, bladder cancer, cancers of the gastrointestinal tract and various leukemias.

The invention relates to a pectin-5-fluorouracil colon cancer two-targeting prodrug and the preparation method thereof, and mainly synthesizes a two-targeting prodrug for colon cancer by utilizing an anti-cancer drug, 5-fluorouracil (5-FU), and pectin. The two-targeting prodrug for colon cancer is used for treating colon cancer and is characterized in that the 6-digit carboxyl is utilized to be combined with 5-FU directly or through different bridging groups to synthesize a series of two-targeting prodrugs for colon cancer. The prodrug first targets 5-FU to the colon by utilizing pectin to realize colon positioned release, and then 5-FU-galactose is identified through high expression of colon cancer galactin-3, and then 5-Fu is targeted to the colon cancer cells to realize two-targeting of colon cancer to treat colon cancer. The prodrug improves the selectivity of 5-FU greatly, enhances the curative effect and reduces adverse reactions. In addition, the hydrolysis fragments of pectin play a role in resisting tumor metastasis and can have a synergic action with 5-FU. The pectin-5-fluorouracil two-targeting prodrug for colon cancer focuses on the drug design ideas of drug delivery, targeting and coordination; therefore, the prodrug achieves the goal of high selectivity, high efficiency and low toxicity.

The invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound, a preparing method, an application and a drug composite containing the compound thereof. More specifically, the invention discloses a 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound as shown in the formula I, a preparing method and an application thereof. By the growth inhibition test of various tumour cell lines (human breast cancer cells MDA-MB-435, p53-deleted poorly differentiated colorectal adenocarcinoma cells Hct116p53-/-, p53-enriched poorly differentiated colorectal adenocarcinoma cells Hct116p53+/+, human breast cancer cells Mcf-7, NIH189, human breast cancer cells SkBr-3, prostatic cancer cells LnCap, LnHer, human colorectal cancer cells HT29 and human ovarian cancer cellsHEY), the compound has favourable inhibition activity for the above tumour cells and can treat diseases caused by tumour cell malignant proliferation. The invention also discloses a drug composite containing the compound.

The invention relates to a method for extracting purple corn pigment. The purple corn pigment according with the conventional international standards is extracted by eleven steps, namely sorting and crushing, extraction with acid water, rough filtration and cooling, filtration of kieselguhr, filtration with a ceramic composite membrane, adsorption and desorption, concentration with a nano-filtration membrane, evaporation concentration, separation, spray drying, and obtaining of a finished product; the raw materials and the extraction equipment used in the extraction method are conventional materials and equipment, so the method is suitable for large-batch production; the extracted purple corn pigment has unique physiological functions of resisting oxidation, softening blood vessels, preventing and killing colon cancer cells and the like, and can be applied in the fields of food, health-care products and medicine; and the production mode is energy-saving and environment-friendly.

The invention discloses 1, 5-diaryl-1, 2, 4-triazole compounds or pharmaceutically acceptable salts thereof shown as structural formula (I)-(III), and pharmaceutical compositions containing the compounds. The invention also discloses application of the compounds or pharmaceutically acceptable salts thereof in preparation of drugs for treatment of various malignant tumors and tumor metastasis related diseases. The compounds shown as formula (I)-(III) can realize concentration gradient dependent inhibition of the proliferation, invasion, infiltration and the like of breast cancer cells, prostate cancer cells, colon cancer cells, liver cancer cells, non-small cell lung cancer cells, bladder cancer cells and other tumor cells, have low toxicity, and have wide application prospects in bio-pharmaceutical industry.